Short or tall? Curly hair or straight? DNA holds those answers, but it can also reveal much more. In the September 8 issue of Nature Genetics, scientists led by Aliza and Thomas Wingo at the ...

Plasma p-tau217 has rapidly pushed to the forefront of Alzheimer’s biomarkers, proving as accurate at predicting plaques as amyloid PET. However, it is less clear how well this blood marker stacks up ...

Gotcha! Scientists spot where, and possibly how, p-tau217 first appears in the brain. In a postmortem study of individuals spanning the Alzheimer’s disease spectrum, researchers led by Michiko Sekiya ...

With amyloid immunotherapy in clinical use, scientists need to find better ways to identify the patients most at risk of developing ARIA (see part 16 of this series). One of the biggest danger signs, ...

This approach uses mesenchymal stem cells isolated from a patient’s own fat tissue to treat neurodegenerative diseases. The stem cells are supposed to assist in repair of damaged tissue and ...

This interactive resource organizes decades of data on biomarkers for Alzheimer's disease. Biomarker measurements from the cerebrospinal fluid and blood are curated from the primary literature and ...

Species: Mouse Genes: SNCA Modification: SNCA: Transgenic Disease Relevance: Parkinson's Disease Strain Name: B6;DBA-Tg(Thy1-SNCA)61Ema Genetic Background: (C57BL/6 x DBA/2)F1 (strain of origin) ...

THY-Tau22 mice are a model for tau aggregation, a pathological hallmark of Alzheimer's disease as well as numerous tauopathies. With age these mice develop a variety of tau-related neuropathological ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

Biogen has thrown in the towel on its controversial anti-amyloid antibody aducanumab. The company announced January 31 that it would stop all development of the drug, and halt the post-market, ...